We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint
Read MoreHide Full Article
Novo Nordisk A/S ((NVO - Free Report) ) announced headline results from the SUSTAIN FORTE study, an efficacy and safety study with once-weekly semaglutide 2.0 mg versus once-weekly semaglutide 1.0 mg as add-on to metformin and/or sulfonylureas in 961 people with type II diabetes in need for treatment intensification. The phase IIIb study achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c of 2.2% at week 40 with semaglutide 2.0 mg compared with a 1.9% reduction with semaglutide 1.0 mg.
Shares of the company have increased 17% year to date compared with the industry’s growth of 2.3%.
The results also showed that from a mean baseline body weight of 99.3 kg, people treated with semaglutide 2.0 mg experienced a statistically significant and superior weight loss of 6.9 kg compared with 6.0 kg with semaglutide 1.0 mg. People treated with semaglutide 2.0 mg experienced a statistically non-significant weight loss of 6.4 kg compared with 5.6 kg with semaglutide 1.0 mg. The study showed that patients in poor glycaemic control increase the likelihood of achieving their HbA1c target when treated with semaglutide 2.0 mg.
We remind investors that semaglutide 1.0 mg is approved under the brand name Ozempic for the treatment of type II diabetes.
Novo Nordisk has a strong presence in the Diabetes care market, with one of the broadest diabetes portfolios in the industry. The company has improved its global diabetes value market share from 28.4% to 29.2% over the past 12 months, driven by an improved global insulin market share and expansion of the GLP-1 segment.
ASLAN’s loss per share estimates have narrowed from 42 cents to 40 cents for 2020 and from 60 cents to 57 cents for 2021 over the past 60 days. Shares of the company have decreased 19.7% year to date.
Abeona’sloss per share estimates have narrowed from 96 cents to 88 cents for 2020 and from 69 cents to 64 cents for 2021 over the past 60 days. Shares of the company have increased 60.8% year to date.
Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days. Shares of the company have decreased 29.9% year to date.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Image: Bigstock
Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint
Novo Nordisk A/S ((NVO - Free Report) ) announced headline results from the SUSTAIN FORTE study, an efficacy and safety study with once-weekly semaglutide 2.0 mg versus once-weekly semaglutide 1.0 mg as add-on to metformin and/or sulfonylureas in 961 people with type II diabetes in need for treatment intensification. The phase IIIb study achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c of 2.2% at week 40 with semaglutide 2.0 mg compared with a 1.9% reduction with semaglutide 1.0 mg.
Shares of the company have increased 17% year to date compared with the industry’s growth of 2.3%.
The results also showed that from a mean baseline body weight of 99.3 kg, people treated with semaglutide 2.0 mg experienced a statistically significant and superior weight loss of 6.9 kg compared with 6.0 kg with semaglutide 1.0 mg. People treated with semaglutide 2.0 mg experienced a statistically non-significant weight loss of 6.4 kg compared with 5.6 kg with semaglutide 1.0 mg. The study showed that patients in poor glycaemic control increase the likelihood of achieving their HbA1c target when treated with semaglutide 2.0 mg.
We remind investors that semaglutide 1.0 mg is approved under the brand name Ozempic for the treatment of type II diabetes.
Novo Nordisk has a strong presence in the Diabetes care market, with one of the broadest diabetes portfolios in the industry. The company has improved its global diabetes value market share from 28.4% to 29.2% over the past 12 months, driven by an improved global insulin market share and expansion of the GLP-1 segment.
Novo Nordisk AS Price
Novo Nordisk AS price | Novo Nordisk AS Quote
Zacks Rank & Stocks to Consider
Novo Nordisk currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector include ASLAN Pharmaceuticals Ltd. (ASLN - Free Report) , Abeona Therapeutics Inc. and Alimera Sciences Inc. (ALIM - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ASLAN’s loss per share estimates have narrowed from 42 cents to 40 cents for 2020 and from 60 cents to 57 cents for 2021 over the past 60 days. Shares of the company have decreased 19.7% year to date.
Abeona’sloss per share estimates have narrowed from 96 cents to 88 cents for 2020 and from 69 cents to 64 cents for 2021 over the past 60 days. Shares of the company have increased 60.8% year to date.
Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days. Shares of the company have decreased 29.9% year to date.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>